S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:NRC

National Research (NRC) Stock Price, News & Analysis

$39.40
-0.18 (-0.45%)
(As of 03/27/2024 ET)
Today's Range
$39.30
$39.85
50-Day Range
$36.87
$40.95
52-Week Range
$36.21
$47.25
Volume
55,577 shs
Average Volume
62,416 shs
Market Capitalization
$939.69 million
P/E Ratio
31.52
Dividend Yield
1.22%
Price Target
N/A

National Research MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.15% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.32mentions of National Research in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$8.30 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.72 out of 5 stars

Business Services Sector

278th out of 313 stocks

Commercial Physical Research Industry

11th out of 11 stocks

NRC stock logo

About National Research Stock (NASDAQ:NRC)

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

NRC Stock Price History

NRC Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
The U.S. Is Betting Big on Small Nuclear Reactors
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Can CAA get BJP lots of votes? Depends
See More Headlines
Receive NRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for National Research and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/12 Dividend
12/28/2023
Dividend Payable
1/12/2024
Last Earnings
2/13/2024
Ex-Dividend for 4/15 Dividend
3/27/2024
Today
3/28/2024
Dividend Payable
4/15/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:NRC
Employees
435
Year Founded
1981

Profitability

Net Income
$30.97 million
Pretax Margin
26.90%

Debt

Sales & Book Value

Annual Sales
$148.58 million
Cash Flow
$1.52 per share
Book Value
$2.02 per share

Miscellaneous

Free Float
23,282,000
Market Cap
$939.69 million
Optionable
Optionable
Beta
0.42

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael D. Hays (Age 69)
    Founder, CEO, President & Director
    Comp: $131.65k
  • Ms. Helen L. Hrdy (Age 58)
    Chief Customer Officer
    Comp: $291.31k
  • Mr. Christophe Louvion
    Chief Product & Technology Officer
  • Mr. Andy Monnich
    Chief Corporate Development Officer
  • Mr. Jon Boumstein
    Chief Delivery Officer
  • Dr. Gregory Makoul M.S.
    Ph.D., Chief Transformation Officer
  • Mr. Jason Hahn
    Chief Revenue Officer
  • Linda Stacy
    Vice President of Finance
  • Megan Charko
    Senior Manager of Content Marketing

NRC Stock Analysis - Frequently Asked Questions

How have NRC shares performed in 2024?

National Research's stock was trading at $39.56 at the start of the year. Since then, NRC stock has decreased by 0.4% and is now trading at $39.40.
View the best growth stocks for 2024 here
.

When is National Research's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our NRC earnings forecast
.

How were National Research's earnings last quarter?

National Research Co. (NASDAQ:NRC) issued its quarterly earnings results on Tuesday, February, 13th. The company reported $0.36 earnings per share for the quarter. The firm had revenue of $38 million for the quarter. National Research had a trailing twelve-month return on equity of 47.79% and a net margin of 20.84%.

How often does National Research pay dividends? What is the dividend yield for National Research?

National Research announced a quarterly dividend on Tuesday, February 13th. Shareholders of record on Friday, March 29th will be given a dividend of $0.12 per share on Monday, April 15th. This represents a $0.48 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Wednesday, March 27th.
Read our dividend analysis for NRC
.

Is National Research a good dividend stock?

National Research (NASDAQ:NRC) pays an annual dividend of $0.48 per share and currently has a dividend yield of 1.21%. The dividend payout ratio is 38.40%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for NRC.

What ETF holds National Research's stock?

Small Cap US Equity Select ETF holds 16,946 shares of NRC stock, representing 2.76% of its portfolio.

What is Michael D. Hays' approval rating as National Research's CEO?

85 employees have rated National Research Chief Executive Officer Michael D. Hays on Glassdoor.com. Michael D. Hays has an approval rating of 87% among the company's employees.

What other stocks do shareholders of National Research own?

Based on aggregate information from My MarketBeat watchlists, some companies that other National Research investors own include Altria Group (MO), Enterprise Products Partners (EPD), AbbVie (ABBV), Dominion Energy (D), Gilead Sciences (GILD), Pfizer (PFE), Toronto-Dominion Bank (TD), Verizon Communications (VZ), Wells Fargo & Company (WFC) and TD Ameritrade (AMTD).

Who are National Research's major shareholders?

National Research's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.81%), Vanguard Group Inc. (3.92%), Conestoga Capital Advisors LLC (3.18%), Dimensional Fund Advisors LP (2.59%), QV Investors Inc. (1.61%) and Northern Trust Corp (1.12%). Insiders that own company stock include Amandla Mk Trust, Jona S Raasch and Kevin R Karas.
View institutional ownership trends
.

How do I buy shares of National Research?

Shares of NRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does National Research have any subsidiaries?
The following companies are subsidiares of National Research: National Research Corporation Canada, PatientWisdom Inc., and The Governance Institute.
Read More
This page (NASDAQ:NRC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners